Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.
Clinical trial details
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Identifier
PM14-A-002-20
Sponsor
PHARMA MAR, S.A. SOCIEDAD UNIPERSONAL
Principal Investigator
MARIA VIEITO VILLAR
Service
Oncology
Study details
Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Cytotoxic
Phase: I
Randomization: Non-randomized
Molecular details
Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable
